Breast Cancer Update .com - Meet The Professors 2004 Vol2, Issue 3

You are here: Home: Meet The Professors Vol. 3 Issue 2 2005: Editor's office

EDITOR
Neil Love, MD

ASSOCIATE EDITORS
Michelle Paley, MD
Richard Kaderman, PhD

WRITERS
Lilliam Sklaver Poltorack,
PharmD
Sally Bogert, RNC, WHCNP
Douglas Paley
Kathryn Ault Ziel, PhD

CME DIRECTOR
Michelle Paley, MD

CONTENT VALIDATION
Margaret Peng

ART DIRECTOR
Tamara Dabney

SENIOR DESIGNER
Christina Brigham

DESIGN QC DIRECTOR
Ben Belin

GRAPHIC DESIGNERS
Jason Cunnius
Fernando Rendina
Maria Schaefer

DIRECTOR, CREATIVE
AND COPY EDITING
Aura Herrmann

PRODUCTION
EDITOR
Alexis Oneca

COPY EDITORS
Sandy Allen
Cirri Nottage
Joy Davis
Pat Morrissey/Havlin
Susan Petrone

AUDIO PRODUCTION
Frank Cesarano

TECHNICAL SERVICES
Arly Ledezma

WEB DESIGN
John Ribeiro

PRODUCTION MANAGER
Patricia Kappes

EDITORIAL ASSISTANTS
Patricia McWhorter
Raquel Segura
Tere Sosa
Ginelle Suarez
Arlene Thorstensen

CONTACT INFORMATION:
Neil Love, MD

RESEARCH TO PRACTICE
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131
Fax: (305) 377-9998
Email: NLove@ResearchToPractice.net

FOR CME INFORMATION:
Melissa Vives,
Associate CME Administrator
Email: MVives@ResearchToPractice.net

© Research To Practice, 2005. All rights reserved.

This program is supported by an education grant from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Roche Laboratories Inc

The audio tapes, compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Table of Contents

Home

Editor's Note:
Til death do us part

CASE 1: A 36-year-old woman with a family history of breast cancer and a poorly differentiated, node-negative IDC of the breast who wishes to retain her fertility (from the practice of Dr Richard S Zelkowitz)

- Select publications

Case 2: A 48-year-old woman with an ER/PR-negative, HER2-positive invasive ductal carcinoma with 11/16 positive nodes who developed CNS and bone metastases three years after local and adjuvant systemic therapy (from the practice of Dr Leonard J Seigel)

- Select publications

Case 3: A 73-year-old woman with ER/PR-positive, node-positive breast cancer who was switched to exemestane after three years of adjuvant tamoxifen (from the practice of Dr Arnold S Blaustein)

- Select publications

Case 4: A woman in her late forties diagnosed with a small, node-negative breast tumor who developed a sternal metastasis after two and one half years of tamoxifen with a shift in tumor phenotype from the primary lesion (from the practice of Dr Lowell L Hart)

- Select publications

Case 5: A 67-year-old woman a large ER/PR-positive, HER2-negative infiltrating ductal carcinoma with two positive lymph nodes (from the practice of Dr Lawrence A Tepper)

- Select publications

Case 6: A 41-year-old woman with an ER/PR-positive, HER2-negative breast tumor who had significant residual disease after AC and docetaxel neoadjuvant therapy (from the practice of Dr Michael S Wertheim)

- Select publications

Case 7: A 72-year-old woman with high-risk, ER/PR-positive breast cancer who refuses treatment with AIs after experiencing uncommon side effects and who subsequently develops a painful metastatic skin nodule and bone metastases (from the practice of Dr David M Dresdner)

- Select publications

CME Information

Faculty and Affiliations

Editor's Office

Home · Contact Us

Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved